STAT6 Nuclear Trafficking Live Cell Imaging Reveals Continuous

Total Page:16

File Type:pdf, Size:1020Kb

STAT6 Nuclear Trafficking Live Cell Imaging Reveals Continuous Live Cell Imaging Reveals Continuous STAT6 Nuclear Trafficking Hui-Chen Chen and Nancy C. Reich This information is current as J Immunol 2010; 185:64-70; Prepublished online 24 May of September 24, 2021. 2010; doi: 10.4049/jimmunol.0903323 http://www.jimmunol.org/content/185/1/64 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/05/21/jimmunol.090332 Material 3.DC1 References This article cites 42 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/185/1/64.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Live Cell Imaging Reveals Continuous STAT6 Nuclear Trafficking Hui-Chen Chen and Nancy C. Reich The STAT6 transcription factor is essential for the development of protective immunity; however, the consequences of its activity can also contribute to the pathogenesis of autoimmune disease. Tyrosine phosphorylation is known to activate STAT6 in response to cytokine stimulation, but there is a gap in our understanding of the mechanisms by which it enters the nucleus. In this study, live cell imaging was used in conjunction with photobleaching techniques to demonstrate the continual nuclear import of STAT6, independent of tyrosine phosphorylation. The protein domain required for nuclear entry includes the coiled coil region of STAT6 and functions similarly before or after cytokine stimulation. The dynamic nuclear shuttling of STAT6 seems to be mediated by the classical importin-a–importin-b1 system. Although STAT6 is imported to the nucleus continually, it accumulates in the nucleus following tyrosine phosphorylation as a result of its ability to bind DNA. These findings will Downloaded from impact diagnostic approaches and strategies to block the deleterious effects of STAT6 in autoimmunity. The Journal of Immunology, 2010, 185: 64–70. eciphering the signaling events initiated by specific effects of STAT6 (12–14). Accurate cellular localization is key to cytokines is critical to understanding their biological the function of a transcription factor, but how the STAT6 protein effects. The STAT6 transcription factor was identified as gains access to the nucleus is not well understood. D http://www.jimmunol.org/ a DNA-binding factor activated in response to IL-4 (1–3). It is now Movement of proteins in and out of the nucleus occurs by known to be required for the generation of Th2 lymphocytes, the passage through nuclear pore complexes that span the nuclear normal function of B lymphocytes, and protection against parasitic membrane (15). Typically, nuclear import of a large protein nematodes (4–7); however, collateral damage accompanies its depends on the presence of a nuclear localization signal (NLS). positive effects in the immune response. Hyperactivity of STAT6 The NLS is recognized by a karyopherin transport receptor that predisposes lymphoproliferative disease and is responsible for facilitates import through the nuclear pore complex (16, 17). The diseases associated with Th2 cell pathologies, like asthma (8–10). classical import receptor consists of a dimer with two distinct Given the considerable evidence that STAT6 contributes to an subunits: an importin-a adapter that binds the NLS and effective immune response and plays a dominant role in asthmatic importin-b that binds importin-a and interacts with the nuclear by guest on September 24, 2021 lung pathology, understanding the mechanisms that regulate its pore complex. In the nucleus, importin-b binds Ran-GTP, lead- nuclear trafficking is essential for therapeutic intervention. ing to release of the NLS cargo. Current knowledge of the nu- STAT6 is a member of the family of signal transducers and clear trafficking of STAT factors has shown that their nuclear activators of transcription and is activated by tyrosine phosphor- import is regulated distinctly (18). For example, nuclear import ylation stimulated in response to Th2 cytokines IL-4 and -13 (11). of the STAT1 factor is conditional and dependent on its dimer- Following cytokine binding to cell-surface receptors, associated ization mediated by tyrosine phosphorylation (19). However, the Janus kinases phosphorylate STAT6 specifically on tyrosine 641. STAT3 transcription factor is imported continually to the nu- Tyrosine phosphorylation promotes the formation of STAT6 dimers cleus, independent of tyrosine phosphorylation (20). The STAT via reciprocal Src homology 2 (SH2) domain and phosphotyrosine molecules share a similar arrangement of functional motifs that interactions. The STAT6 dimer gains the ability to bind DNA tar- including an N terminus, coiled coil domain, DNA-binding do- gets, leading to new gene expression responsible for the biological main, SH2 domain, phosphorylated tyrosine, and carboxyl trans- activation domain. Following tyrosine phosphorylation and Department of Molecular Genetics and Microbiology, Stony Brook University, Stony dimerization, STAT1 gains the function of an NLS within its Brook, NY 11794 DNA-binding domain, whereas STAT3 has a constitutive NLS Received for publication October 15, 2009. Accepted for publication April 18, 2010. within the coiled coil domain, independent of tyrosine phosphor- This work was supported by National Institutes of Health Grant RO1CA122910 (to ylation. N.C.R.). To assess the dynamic movement of STAT6 we used live cell Address correspondence and reprint requests to Dr. Nancy C. Reich, Department of imaging with photobleaching techniques. We provide evidence Molecular Genetics and Microbiology, Stony Brook University, Nicolls Road, Life that STAT6 is imported continually into the nucleus, independent Sciences Building, Stony Brook, NY 11794. E-mail address: nancy.reich@stony brook.edu of tyrosine phosphorylation, and it seems to use the importin- The online version of this article contains supplemental material. a2importin-b1 system. In addition, a region required for NLS Abbreviations used in this paper: anti-pSTAT6, anti-STAT6 phosphotyrosine 641 Ab; function was found to map within the coiled coil domain. c, control; C, cytoplasm; dl, deletion; Fl, fluorescent; FLIP, fluorescence loss in Although nuclear import rates of STAT6 are similar before and photobleaching; FRAP, fluorescence recovery after photobleaching; G, GFP; hIL-4, after tyrosine phosphorylation, nuclear accumulation occurs after human IL-4; impb1, importin-b1; IP, immunoprecipitated; MBP, maltose-binding protein; N, nucleus; NLS, nuclear localization signal; PS, Ponceau S; S, STAT6; phosphorylation, and this is dependent on the DNA-binding abil- SH2, Src homology 2; siRNA, short interfering RNA; STAT6-V5, STAT6 tagged ity of STAT6. Live cell imaging has provided critical insight to the with the V5 epitope; WB, Western blot; wtSTAT6, wild type STAT6. spatial distribution of STAT6, which impacts its function as a tran- Copyright Ó 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00 scription factor. www.jimmunol.org/cgi/doi/10.4049/jimmunol.0903323 The Journal of Immunology 65 Materials and Methods Axiovert 200M microscope using a heating insert coupled with the In- Cell cultures and reagents cubator S (Zeiss). During imaging, the cells were maintained at 37˚C and 5% CO2 using the Zeiss Tempcontrol 37-2 Digital and CTI Controller HeLa and Cos1 cells (American Type Culture Collection, Manassas, VA) 3700. The time-series images for photobleaching assays were taken with were cultured in DMEM with 8% FBS. Cells were treated with human the Zeiss LSM 510 META NLO two-photon laser-scanning microscope rIL-4 (R&D Systems, Minneapolis, MN) at 10 ng/ml. DNA transfections system using a 403 oil objective (Plan-Neofluar, numerical aperture 1.3, were carried out using TransIT-LT1 transfection reagent (Mirus, Madison, differential interference contrast microscopy objective). The excitation WI), according to the manufacturer’s instructions. Rabbit anti-STAT6 Ab wavelength used for GFP was 488 nm, and emission was detected with (Santa Cruz Biotechnology, Santa Cruz, CA), anti-STAT6 phosphotyrosine a 505-nm filter. For fluorescence recovery after photobleaching (FRAP) 641 Ab (anti-pSTAT6) (Cell Signaling Technology, Danvers, MA), and mu- analysis, a region in the nucleus was bleached at 100% power of an argon rine anti-GFP Ab (Roche Diagnostic Systems, Indianapolis, IN) were used laser at 488 nm for 70 s. For fluorescence loss in photobleaching (FLIP) for Western blotting at a 1:1000 dilution. HRP-conjugated anti-rabbit and analysis, a region in the nucleus or cytoplasm was bleached every 12 s at anti-mouse Ig were used as secondary Abs for Western blotting (1:5000). maximum laser intensity for 5 or 50 min. Images were acquired using LSM GFP Ab and murine
Recommended publications
  • Targeting Il13ralpha2 Activates STAT6-TP63 Pathway to Suppress Breast Cancer Lung Metastasis Panagiotis Papageorgis1,2,3*, Sait Ozturk2, Arthur W
    Papageorgis et al. Breast Cancer Research (2015) 17:98 DOI 10.1186/s13058-015-0607-y RESEARCH ARTICLE Open Access Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis Panagiotis Papageorgis1,2,3*, Sait Ozturk2, Arthur W. Lambert2, Christiana M. Neophytou1, Alexandros Tzatsos4, Chen K. Wong2, Sam Thiagalingam2*† and Andreas I. Constantinou1*† Abstract Introduction: Basal-like breast cancer (BLBC) is an aggressive subtype often characterized by distant metastasis, poor patient prognosis, and limited treatment options. Therefore, the discovery of alternative targets to restrain its metastatic potential is urgently needed. In this study, we aimed to identify novel genes that drive metastasis of BLBC and to elucidate the underlying mechanisms of action. Methods: An unbiased approach using gene expression profiling of a BLBC progression model and in silico leveraging of pre-existing tumor transcriptomes were used to uncover metastasis-promoting genes. Lentiviral- mediated knockdown of interleukin-13 receptor alpha 2 (IL13Ralpha2) coupled with whole-body in vivo bioluminescence imaging was performed to assess its role in regulating breast cancer tumor growth and lung metastasis. Gene expression microarray analysis was followed by in vitro validation and cell migration assays to elucidate the downstream molecular pathways involved in this process. Results: We found that overexpression of the decoy receptor IL13Ralpha2 is significantly enriched in basal compared with luminal primary breast tumors as well as in a subset of metastatic basal-B breast cancer cells. Importantly, breast cancer patients with high-grade tumors and increased IL13Ralpha2 levels had significantly worse prognosis for metastasis-free survival compared with patients with low expression.
    [Show full text]
  • Interferons Inhibit Activation of STAT6 by Interleukin 4 in Human Monocytes by Inducing SOCS-1 Gene Expression
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 10800–10805, September 1999 Immunology Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression HAROLD L. DICKENSHEETS*, CHANDRASEKAR VENKATARAMAN†,ULRIKE SCHINDLER†, AND RAYMOND P. DONNELLY*‡ *Division of Cytokine Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892; and †Tularik, Inc., South San Francisco, CA 94080 Edited by William E. Paul, National Institutes of Health, Bethesda, MD, and approved July 8, 1999 (received for review February 16, 1999) ABSTRACT Interferons (IFNs) inhibit induction by IL-4 12), 15-lipoxygenase (15-LO) (13, 14), IL-1 receptor antago- of multiple genes in human monocytes. However, the mecha- nist (IL-1ra) (15–17), and types I and II IL-1 receptors (IL-1R) nism by which IFNs mediate this inhibition has not been (18, 19). Type I IFNs (IFN-␣ and IFN-␤) and type II IFN defined. IL-4 activates gene expression by inducing tyrosine (IFN-␥) inhibit IL-4͞IL-13-induced gene expression in mono- phosphorylation, homodimerization, and nuclear transloca- cytes and B cells. For example, IFN-␥ suppresses IgE synthesis tion of the latent transcription factor, STAT6 (signal trans- by IL-4-stimulated B cells (20–22). IFNs also inhibit IL-4- ducer and activator of transcription-6). STAT6-responsive induced CD23 expression in both B cells (23, 24) and mono- elements are characteristically present in the promoters of cytes (25, 26). Furthermore, IFN-␥ inhibits IL-4- and IL-13- IL-4-inducible genes. Because STAT6 activation is essential induced expression of 15-LO and IL-1ra in monocytes (13, 14, for IL-4-induced gene expression, we examined the ability of 27).
    [Show full text]
  • STAT6-Dependent Fashion CCL23 Expression Is Induced by IL-4 in A
    CCL23 Expression Is Induced by IL-4 in a STAT6-Dependent Fashion Hermann Novak, Anke Müller, Nathalie Harrer, Claudia Günther, Jose M. Carballido and Maximilian Woisetschläger This information is current as of September 28, 2021. J Immunol 2007; 178:4335-4341; ; doi: 10.4049/jimmunol.178.7.4335 http://www.jimmunol.org/content/178/7/4335 Downloaded from References This article cites 47 articles, 20 of which you can access for free at: http://www.jimmunol.org/content/178/7/4335.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 28, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CCL23 Expression Is Induced by IL-4 in a STAT6-Dependent Fashion Hermann Novak, Anke Mu¨ller, Nathalie Harrer, Claudia Gu¨nther, Jose M. Carballido, and Maximilian Woisetschla¨ger1 The chemokine CCL23 is primarily expressed in cells of the myeloid lineage but little information about its regulation is available.
    [Show full text]
  • Allen Gao, M.D., Ph.D
    Allen Gao, M.D., Ph.D. Research/Academic Interests Dr. Gao’s research interests focus on understanding molecular mechanisms associated with progression of castration-resistant prostate cancer and metastasis to bone with the goal of identification of potential therapeutic targets for prostate cancer. Particular emphasis includes microRNAs, aberrant androgen receptor activation by cytokines and transcriptional factors such as Stat3 and NF-kB, targeting cell signaling pathways (AR, IL-6 and Stat3), and mechanisms of drug resistance in prostate cancer. Dr. Gao’s lab was among the first to find that selenium regulates androgen signaling and that IL-4 activates the androgen receptor mediated by NF-B and Stat6, made the discovery that IL-6 signaling in prostate cancer involves Stat3, defined Stat3 and NF-B interactions in prostate cancer, discovered niclosamide as a novel inhibitor of androgen receptor variants (AR-V7), and identified several novel resistance mechanisms to enzalutamide/abiraterone/docetaxel including p52, IL- 6/Stat3, intracrine androgens/AKR1C3, and ABCB1. Dr. Gao has published over 100 peer-reviewed articles in the area of prostate cancer. His research findings such as the discovery of niclosamide as a novel inhibitor of androgen receptor variants have translated into several clinical trials (NCT02807805, NCT03123978) that test the combination treatments with current therapies to advanced resistant prostate cancer. Another recent discovery of indomethacin as an inhibitor of AKR1C3 and synergizing enzalutamide has also translated into clinical trial (NCT02935205) to test the combination treatments with current therapies to advanced resistant prostate cancer. Dr. Gao has served numerous NIH, NCI, DOD and VA merits, and American Cancer Society (ACS) review panels including SPORE and PPG study sections.
    [Show full text]
  • Mast Cell STAT6 IL-4 Induces the Proteolytic Processing Of
    IL-4 Induces the Proteolytic Processing of Mast Cell STAT6 Melanie A. Sherman, Doris R. Powell and Melissa A. Brown This information is current as J Immunol 2002; 169:3811-3818; ; of September 28, 2021. doi: 10.4049/jimmunol.169.7.3811 http://www.jimmunol.org/content/169/7/3811 Downloaded from References This article cites 74 articles, 47 of which you can access for free at: http://www.jimmunol.org/content/169/7/3811.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 28, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology IL-4 Induces the Proteolytic Processing of Mast Cell STAT61 Melanie A. Sherman, Doris R. Powell, and Melissa A. Brown2 IL-4 is a potent, pleiotropic cytokine that, in general, directs cellular activation, differentiation, and rescue from apoptosis. However, in mast cells, IL-4 induces the down-regulation of activation receptors and promotes cell death.
    [Show full text]
  • STAT3 Impairs STAT5 Activation in the Development of IL-9–Secreting T Cells
    STAT3 Impairs STAT5 Activation in the Development of IL-9−Secreting T Cells Matthew R. Olson, Felipe Fortino Verdan, Matthew M. Hufford, Alexander L. Dent and Mark H. Kaplan This information is current as of September 29, 2021. J Immunol published online 14 March 2016 http://www.jimmunol.org/content/early/2016/03/11/jimmun ol.1501801 Downloaded from Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription by guest on September 29, 2021 Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published March 14, 2016, doi:10.4049/jimmunol.1501801 The Journal of Immunology STAT3 Impairs STAT5 Activation in the Development of IL-9–Secreting T Cells Matthew R. Olson,* Felipe Fortino Verdan,*,† Matthew M. Hufford,* Alexander L. Dent,‡ and Mark H. Kaplan*,‡ Th cell subsets develop in response to multiple activating signals, including the cytokine environment. IL-9–secreting T cells develop in response to the combination of IL-4 and TGF-b, although they clearly require other cytokine signals, leading to the activation of transcription factors including STAT5.
    [Show full text]
  • Discrete Roles of STAT4 and STAT6 Transcription Factors in Tuning Epigenetic Modifications and Transcription During T Helper Cell Differentiation
    Immunity Resource Discrete Roles of STAT4 and STAT6 Transcription Factors in Tuning Epigenetic Modifications and Transcription during T Helper Cell Differentiation Lai Wei,1,5 Golnaz Vahedi,1,5 Hong-Wei Sun,2 Wendy T. Watford,1 Hiroaki Takatori,1 Haydee L. Ramos,1 Hayato Takahashi,1 Jonathan Liang,1 Gustavo Gutierrez-Cruz,3 Chongzhi Zang,4 Weiqun Peng,4 John J. O’Shea,1 and Yuka Kanno1,* 1Molecular Immunology and Inflammation Branch 2Biodata Mining and Discovery Section 3Laboratory of Muscle Stem Cells and Gene Regulation NIAMS, National Institutes of Health, Bethesda MD 20892, USA 4Department of Physics, George Washington University, Washington, DC 20052, USA 5These authors contributed equally to this work *Correspondence: [email protected] DOI 10.1016/j.immuni.2010.06.003 SUMMARY constrain immune-mediated damage (Sakaguchi et al., 2008). Thus, the attainment of these cell fates is critical not only for Signal transducer and activator of transcription 4 proper elimination of pathogens, but also for avoidance of (STAT4) and STAT6 are key factors in the specifica- damage to the host (Reiner, 2007). tion of helper T cells; however, their direct roles in The microenvironment of the naive CD4+ T cell greatly influ- driving differentiation are not well understood. Using ences its specification, with a key factor being the cytokine chromatin immunoprecipitation and massive parallel milieu. A major means by which cytokines exert their effect is sequencing, we quantitated the full complement of through activation of signal transducer and activator of transcrip- tion (STAT) family transcription factors, which translocate to the STAT-bound genes, concurrently assessing global nucleus, bind to the regulatory region of genes and induce tran- STAT-dependent epigenetic modifications and scription (Levy and Darnell, 2002; Schindler and Darnell, 1995).
    [Show full text]
  • Rnaseq Analysis Identifies Non-Canonical Role of STAT2 And
    bioRxiv preprint doi: https://doi.org/10.1101/273623; this version posted February 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 RNASeq analysis identifies non-canonical role of STAT2 and IRF9 in 2 the regulation of a STAT1-independent antiviral and 3 immunoregulatory transcriptional program induced by IFNβ and 4 TNFα 5 6 Mélissa K. Mariani1, Pouria Dasmeh2,3, Audray Fortin1, Mario Kalamujic1, Elise Caron1, 7 Alexander N. Harrison1,4 Sandra Cervantes-Ortiz1,5, Espérance Mukawera1, Adrian W.R. 8 Serohijos2,3 and Nathalie Grandvaux1,2* 9 10 1 CRCHUM - Centre Hospitalier de l’Université de Montréal, Québec, Canada 11 2 Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal, 12 Qc, Canada. 13 3 Centre Robert Cedergren en Bioinformatique et Génomique, Université de Montréal, Qc, Canada 14 4 Department of Microbiology and Immunology, McGill University, Qc, Canada 15 5 Department of Microbiology, Infectiology and Immunology, Faculty of Medicine, Université de 16 Montréal, Qc, Canada 17 18 * Correspondence: 19 Corresponding Author 20 [email protected] 21 22 Keywords: Interferon β, TNFα, STAT1, STAT2, IRF9, antiviral, 23 24 Running title: STAT1-independent transcriptional response to IFNβ+TNFα 25 26 27 1 bioRxiv preprint doi: https://doi.org/10.1101/273623; this version posted February 28, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • The Role of Stat5a and Stat5b in Signaling by IL-2 Family Cytokines
    Oncogene (2000) 19, 2566 ± 2576 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc The role of Stat5a and Stat5b in signaling by IL-2 family cytokines Jian-Xin Lin1 and Warren J Leonard*,1 1Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bldg. 10/Rm. 7N252, 9000 Rockville Pike, Bethesda, Maryland MD 20892-1674, USA The activation of Stat5 proteins (Stat5a and Stat5b) is each of the IL-2 family cytokines contains at least one one of the earliest signaling events mediated by IL-2 other component, such as IL-2Rb, IL-4Ra, IL-7Ra and family cytokines, allowing the rapid delivery of signals IL-9Ra (Figure 1), that contributes both to binding and from the membrane to the nucleus. Among STAT family to transduction of speci®c signals (Leonard, 1999). proteins, Stat5a and Stat5b are the two most closely Because the receptors for IL-2 and IL-15 additionally related STAT proteins. Together with other transcription share IL-2Rb (Figure 1), IL-2 and IL-15 have the most factors and co-factors, they regulate the expression of overlapping biological activities of the ®ve cytokines. In the target genes in a cytokine-speci®c fashion. In contrast to IL-4, IL-7 and IL-9, the receptors for IL-2 addition to their activation by cytokines, activities of and IL-15 also have third components, IL-2Ra and IL- Stat5a and Stat5b, as well as other STAT proteins, are 15Ra (Lin and Leonard, 1997; Waldmann et al., 1998; negatively controlled by CIS/SOCS/SSI family proteins.
    [Show full text]
  • Analysis of Phosphorylated STAT Protein Signaling in Lymphocytes Using Flow Cytometry
    Application Note Cell Analysis Analysis of Phosphorylated STAT Protein Signaling in Lymphocytes Using Flow Cytometry Author Abstract Agilent Technologies, Inc. This application note examines the phosphorylation of signal transducer and activator of transcription (STAT) proteins in response to cytokine stimulation using a flow cytometry–based phosphoflow technique and the Agilent NovoCyte flow cytometer. The results demonstrate the efficacy of this approach for the rapid, quantitative, scalable, and multiparameter detection of phosphorylated protein in single cells. Introduction many cellular events including T and blotting, and mass spectrometry. B cell signaling, cell metabolism, cell Western blotting is the most commonly Protein phosphorylation is the growth, apoptosis, and other processes. used but has shortcomings; it is biological process of transferring semiquantitative, time-consuming, and Cytokines are a group of small a phosphate group to a substrate requires a large amount of starting secreted proteins important for protein, which primarily occurs on material. Also, cell separation may be immune cell-to-cell communication, tyrosine, serine, and threonine residues. required to isolate a pure population of a immune cell activation, differentiation, Protein phosphorylation can cause cells from a heterogeneous mixture. conformational changes, changes and migration towards the site of Analysis of phosphorylated proteins by in protein activity, or protein-protein inflammation/infection. Cytokines bind to flow cytometry or phosphoflow was interactions. This event can also initiate receptors on the cell surface and activate first described in the early 2000s. By a phosphorylation signaling cascade intracellular cascades, such as the Janus combining a phosphoflow methodology leading to a sequence of protein kinase (JAK)/STAT pathway. STATs are with cell surface antibody staining, rare phosphorylation events.
    [Show full text]
  • STAT6, PBX2, and PBRM1 Emerge As Predicted Regulators of 452 Differentially Expressed Genes Associated with Puberty in Brahman Heifers
    UC Davis UC Davis Previously Published Works Title STAT6, PBX2, and PBRM1 Emerge as Predicted Regulators of 452 Differentially Expressed Genes Associated With Puberty in Brahman Heifers. Permalink https://escholarship.org/uc/item/4d39w8k7 Journal Frontiers in genetics, 9(MAR) ISSN 1664-8021 Authors Nguyen, Loan T Reverter, Antonio Cánovas, Angela et al. Publication Date 2018 DOI 10.3389/fgene.2018.00087 Peer reviewed eScholarship.org Powered by the California Digital Library University of California fgene-09-00087 March 16, 2018 Time: 18:37 # 1 ORIGINAL RESEARCH published: 20 March 2018 doi: 10.3389/fgene.2018.00087 STAT6, PBX2, and PBRM1 Emerge as Predicted Regulators of 452 Differentially Expressed Genes Associated With Puberty in Brahman Heifers Loan T. Nguyen1,2, Antonio Reverter3, Angela Cánovas4, Bronwyn Venus5, Stephen T. Anderson6, Alma Islas-Trejo7, Marina M. Dias8, Natalie F. Crawford9, Sigrid A. Lehnert3, Juan F. Medrano7, Milt G. Thomas9, Stephen S. Moore5 and Marina R. S. Fortes1,5* 1 School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD, Australia, Edited by: 2 Faculty of Biotechnology, Vietnam National University of Agriculture, Hanoi, Vietnam, 3 CSIRO Agriculture and Food, Haja N. Kadarmideen, Queensland Bioscience Precinct, St. Lucia, QLD, Australia, 4 Centre for Genetic Improvement of Livestock, Department of Technical University of Denmark, Animal Biosciences, University of Guelph, Guelph, ON, Canada, 5 Queensland Alliance for Agriculture and Food Innovation, Denmark The University of Queensland, St. Lucia, QLD, Australia, 6 School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia, 7 Department of Animal Science, University of California, Davis, Davis, CA, United States, Reviewed by: 8 Departamento de Zootecnia, Faculdade de Ciências Agráìrias e Veterináìrias, Universidade Estadual Paulista Júlio de Shikai Liu, Mesquita Filho, São Paulo, Brazil, 9 Department of Animal Science, Colorado State University, Fort Collins, CO, United States Ocean University of China, China Kieran G.
    [Show full text]
  • Inflammation and NF-B Signaling in Prostate Cancer
    cells Review Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications Jens Staal 1,2 ID and Rudi Beyaert 1,2,* ID 1 VIB-UGent Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, 9052 Ghent, Belgium 2 Department of Biomedical Molecular Biology, Ghent University, 9000 Ghent, Belgium * Correspondence: [email protected]; Tel.: +32-9-3313770 Received: 31 July 2018; Accepted: 27 August 2018; Published: 29 August 2018 Abstract: Prostate cancer is a highly prevalent form of cancer that is usually slow-developing and benign. Due to its high prevalence, it is, however, still the second most common cause of death by cancer in men in the West. The higher prevalence of prostate cancer in the West might be due to elevated inflammation from metabolic syndrome or associated comorbidities. NF-κB activation and many other signals associated with inflammation are known to contribute to prostate cancer malignancy. Inflammatory signals have also been associated with the development of castration resistance and resistance against other androgen depletion strategies, which is a major therapeutic challenge. Here, we review the role of inflammation and its link with androgen signaling in prostate cancer. We further describe the role of NF-κB in prostate cancer cell survival and proliferation, major NF-κB signaling pathways in prostate cancer, and the crosstalk between NF-κB and androgen receptor signaling. Several NF-κB-induced risk factors in prostate cancer and their potential for therapeutic targeting in the clinic are described. A better understanding of the inflammatory mechanisms that control the development of prostate cancer and resistance to androgen-deprivation therapy will eventually lead to novel treatment options for patients.
    [Show full text]